Shattuck Labs, Inc.
NASDAQ:STTKBiotechnology
+$0.11 today
- Market cap
- $455.24M
- Beta
- 1.09
- P/E (TTM)
- -10.9
- EPS (TTM)
- -$0.44
Volume 2.08M
Average 0.69M
STTK Free Cash Flow
Operating cash flow minus capital expenditures: cash available for debt repayment, dividends, and buybacks.
Shattuck Labs, Inc.NASDAQ: STTK
Free Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Free cash flow growth accelerates
Q1 FY2026 free cash flow of $13.36M (cash outflow) rose 11.0% year over year, ahead of the -26.9% change in trailing-twelve-month free cash flow. Sequentially, it rose 57.4% from the prior quarter. Over 3 fiscal years it compounded at -27.8% a year.
Context
- Free cash flow amounted to 3995.3% of revenue in FY2025, up 2936.5 pp from a year earlier.
- Free cash flow grew in size in 0 of the last 3 fiscal years.
- FY2025 was the smallest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +11.0% holds above the trailing-twelve-month pace of -26.9%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Free Cash Flow history
USD · from the cash flow
- Latest · FY2025
- (39.95M) USD
- Year-over-year change
- +34.0%
| Period | Period end | Free Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (39.95M) | +34.0% |
| FY2024 | 2024-12-31 | (60.57M) | +25.8% |
| FY2023 | 2023-12-31 | (81.64M) | +23.1% |
| FY2022 | 2022-12-31 | (106.11M) | -63.1% |
| FY2021 | 2021-12-31 | (65.04M) | — |
Free Cash Flow vs competitors
How STTK compares with its peers on the latest reported figures
- Peers report in different currencies, so free cash flow is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -26.9% is the 6th highest of 9, against a peer median of +8.9%.
- Free cash flow amounts to 4128.2% of revenue for STTK, versus a peer median of 57.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $4.39B USD | +12754.9% | +925.8% | — | |
| LTM Sep 2026 | $216.06M USD | -38.6% | +2.4% | 57.0% | |
| LTM Mar 2026 | $148.43M USD | -8786.2% | +15.9% | 1249.1% | |
| LTM Mar 2026 | $53.6M USD | +72.0% | — | 23.6% | |
| LTM Mar 2026 | $41.28M USD | -26.9% | -27.8% | 4128.2% | |
| LTM Mar 2026 | $34.03M USD | -225.9% | — | — | |
| LTM Jun 2026 | $33.86M USD | +39.5% | -19.6% | — | |
| LTM Sep 2026 | $27.3M USD | -10.9% | +0.1% | — | |
| LTM Mar 2026 | $17.27M USD | +28.6% | +3.8% | — | |
NBPNovaBridge Biosciences | LTM Sep 2025 | CN¥13.15M CNY | — | -73.8% | — |
| Peer median (excluding STTK) | — | +8.9% | +2.4% | 57.0% | |
Competitors are the stored peer set for STTK. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (44.97M) | (101.95M) | (87.3M) | (75.41M) | (48.81M) |
| Depreciation & Amortization | 1.38M | 3.07M | 4.04M | 3.83M | 3.69M |
| Deferred Income Tax | 3.04M | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 5.47M | 6.46M | 6.94M | 9.55M | 7M |
| Change in Working Capital | (23.55M) | (4.46M) | (4.1M) | 3.02M | (785K) |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 7.87M | (2.84M) | (5.63M) | 832K | (318K) |
| Other Working Capital | (31.41M) | (1.62M) | 1.53M | 2.19M | (467K) |
| Other Non-Cash Items | 1.52M | 2.38M | (816K) | (1.5M) | (971K) |
| Operating Cash Flow | (57.12M) | (94.5M) | (81.23M) | (60.52M) | (39.88M) |
| Capital Expenditures | (7.93M) | (11.61M) | (407K) | (59K) | (71K) |
| Acquisitions (Net) | 2.52M | 104K | 0 | 0 | 0 |
| Purchases of Investments | (204.09M) | (132.38M) | (79.73M) | (93.55M) | (43.42M) |
| Sales of Investments | 201.58M | 193.33M | 191M | 85.1M | 35.6M |
| Other Investing Activities | (2.52M) | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (10.44M) | 49.44M | 110.86M | (8.51M) | (7.89M) |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 1.93M | 171K | 48.67M | (17K) | 44.48M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 0 | (53K) | 804K | (65K) |
| Financing Cash Flow | 1.93M | 171K | 48.62M | 787K | 44.57M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (65.63M) | (44.89M) | 78.25M | (68.24M) | (3.2M) |
| Free Cash Flow | (65.04M) | (106.11M) | (81.64M) | (60.57M) | (39.95M) |
Shattuck Labs, Inc.
NASDAQ:STTK
Intrinsic Alpha fair value
Locked
Current Price
$4.47
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.